In the setting of diabetic macular edema (DME) with visual loss, multiple studies have demonstrated the remarkable visual and anatomic value of consistent anti-vascular endothelial growth factor (VEGF) pharmacotherapy initiated early in the disease process [2,3,4,5]. This evidence concerns the gene VEGFA and diabetic macular edema.